We also included MYC/PVT1-neutral cell lines (no amplification and no translocation): U2OS (osteosarcoma), BxPC-3 (pancreatic ductal adenocarcinoma) and DU145 (prostate cancer) as controls. This evidence concerns the gene MYC and prostate cancer.